As an experienced IVF consultant, I hear the exact same question from nearly every patient reviewing their treatment protocol: Is PGT-A really necessary? You have mapped out your fertility journey. You understand the injection schedules, the egg retrieval process, and the sheer emotional toll of it all. Then comes the paperwork for laboratory add-ons. The price tag attached to Preimplantation Genetic Testing for Aneuploidies (PGT-A) stares back at you. It requires a significant upfront investment.
For hopeful parents, a failed embryo transfer or a miscarriage is a crushing blow. Every embryo is precious. Losing a pregnancy due to a chromosomal abnormality feels like a preventable tragedy, especially considering the time and capital already invested in the cycle. This creates paralyzing indecision. Are you paying for peace of mind, or are you paying for a medical necessity?
You do not need guesswork; you need actionable data. We must evaluate the true PGT-A genetic screening necessity based on your specific biological reality. Let’s bypass the marketing speak and break down the actual cost-benefit ratio of testing embryos. We will compare women over 35 versus under 35 using clinic-specific live birth rate metrics.
Discussing PGT-A With Your IVF Consultant: What You Need to Know
Under a standard microscope, a genetically normal embryo and a genetically abnormal embryo can look completely identical. An embryologist might give a day-5 blastocyst a perfect “AA” grade based purely on aesthetics. Yet, inside, it could be missing a chromosome or carrying an extra one (aneuploidy).
PGT-A changes the equation. An embryologist carefully removes a few cells from the trophectoderm, the part of the embryo that becomes the placenta, leaving the fetal cells untouched. These cells are sent to a genetics lab to count the chromosomes. We are looking for the magic number: 46.
Transferring a chromosomally normal (euploid) embryo dramatically reduces miscarriage rates and accelerates your time to a live birth. But does everyone need it? Absolutely not.
The Core Dilemma: Age vs. Chromosomal Integrity
When patients first search for a “fertility check up near me,” they are usually focused on AMH levels or sperm counts. However, egg quality, specifically chromosomal integrity, is arguably the heaviest weight on the scale of IVF success. This integrity is strictly tied to maternal age.
Women Under 35: The Cost-Benefit Reality
If you are under 35, your eggs are generally highly efficient at dividing chromosomes correctly. In this bracket, roughly 60% to 70% of embryos created in an IVF cycle will naturally be euploid.
Does PGT-A improve live birth rates here? Barely. Studies consistently show that for young women with no history of miscarriage, the live birth rate per transfer is nearly identical whether you test the embryos or not. You are essentially paying thousands of extra dollars to confirm what biology is already doing well. The financial sting outweighs the medical benefit.
Women Over 35: The Game Changer
The narrative flips entirely after age 35. Aneuploidy rates rise sharply. By age 38, nearly 65% to 70% of embryos may be chromosomally abnormal. By age 40, that number can exceed 80%.
For patients over 35, the PGT-A genetic screening necessity transitions from an “optional add-on” to a highly strategic clinical tool. Without testing, you might endure three or four failed transfers before finding the one healthy embryo. Each failed transfer costs money, requires weeks of hormone preparation, and exacts a heavy emotional toll. Here, paying for PGT-A upfront actually saves money by preventing doomed transfer cycles and minimizing miscarriage trauma.
Data-Driven Cost-Benefit Analysis: PGT-A Success Rates
To clarify the financial and medical reality, let’s look at the estimated impact of PGT-A on live birth rates across different age brackets.
| Patient Age Bracket | Estimated Natural Euploid Rate | Live Birth Rate (Unscreened Transfer) | Live Birth Rate (PGT-A Screened Transfer) | The Cost-Benefit Verdict |
| Under 35 | 60% – 70% | ~50% – 55% | ~55% – 60% | Low Necessity. Marginal gain for a high upfront cost. Better to invest in standard single embryo transfers. |
| 35 to 37 | 45% – 55% | ~35% – 40% | ~50% – 60% | Moderate Necessity. Highly recommended if the retrieval yields multiple blastocysts to help select the best one. |
| 38 to 40 | 25% – 40% | ~20% – 25% | ~50% – 55% | High Necessity. Significantly lowers time-to-pregnancy and prevents painful transfer failures. Worth the investment. |
| Over 40 | 10% – 20% | < 10% | ~45% – 50% | Critical Necessity. Cost-effective. Prevents the financial drain of transferring multiple aneuploid embryos. |
Note: Live birth rates fluctuate based on individual clinical factors, including uterine receptivity and sperm quality.
Hidden Variables: When Testing is Mandatory
Age is the primary driver, but it isn’t the only one. Even if you are 28 years old, an IVF consultant will immediately pivot to recommending PGT-A if you fall into specific diagnostic categories:
- Recurrent Pregnancy Loss (RPL): If you have suffered two or more consecutive miscarriages, we must rule out chromosomal abnormalities as the root cause.
- Recurrent Implantation Failure (RIF): When perfectly graded, untested embryos repeatedly fail to implant in a highly receptive uterus.
- Severe Male Factor Infertility: Extreme cases of low sperm motility or morphology can contribute to higher rates of embryonic aneuploidy.
Making Your Decision at Karthika Woman and Child Care
When you type “fertility near me” into a search bar, you are looking for a partner who prioritizes your overall well-being over upselling clinic services. At Karthika Woman and Child Care, we do not believe in blanket protocols.
Our approach to reproductive health, IVF, and PCOS management is strictly individualized. If the data dictates that PGT-A will save you time, money, and heartache, we will champion it. If your age and medical history suggest it is an unnecessary expense, we will advise against it so you can allocate those funds toward your growing family.
Frequently Asked Questions (FAQ)
Does the PGT-A biopsy damage the embryo?
In the hands of a highly skilled embryologist, the risk of damage is incredibly low, typically less than 1%. We only biopsy Day-5 or Day-6 blastocysts, taking cells exclusively from the future placenta (trophectoderm), leaving the inner cell mass (the future baby) completely undisturbed.
Is PGT-A 100% accurate?
No medical test is flawless. PGT-A is highly accurate, generally boasting a 97% to 99% accuracy rate in detecting missing or extra chromosomes. However, there is a small margin for error, including the phenomenon of “mosaic” embryos, where the biopsied cells do not perfectly match the rest of the embryo.
Does transferring a normal PGT-A embryo guarantee a pregnancy?
No. A euploid embryo is the most critical piece of the puzzle, but it still requires a receptive uterine environment to implant. Factors like adenomyosis, thin endometrial lining, or undetected autoimmune issues can still impact implantation. However, a euploid embryo gives you the absolute highest statistical probability of success.
